Teladoc Health, Inc.

NYSE:TDOC

Medical - Healthcare Information Services

Healthcare
$8.06 +2.57%

+$0.20 today

Market cap
$1.47B
Beta
2.14
P/E (TTM)
-8.1
EPS (TTM)
-$0.96
52W Low $4.40High $9.77

Volume 3.96M

Average 4.68M

TDOC Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Teladoc Health, Inc.NYSE: TDOC

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $63.84M (cash outflow) fell 31.4% year over year, ahead of the -83.1% change in trailing-twelve-month net income. Sequentially, it rose 153.9% from the prior quarter. Over 3 fiscal years it compounded at -75.5% a year.

Context

  • Net income amounted to 7.9% of revenue in FY2025, down 31.0 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 16 analysts of -$155.33M (-22.5%) for the fiscal year ending Dec 2026, a step up from the -80.0% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$63.84M+153.9% QoQ
Last fiscal yearDec 2025
-$200.32M-80.0% YoY
LTMMar 2026
-$171.15M-83.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-31.4%+39.1%+70.4 pp
1 year-80.0%-22.5%+57.5 pp
3-year CAGR-75.5%-15.5%+60.1 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(200.32M) USD
Year-over-year change
+80.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How TDOC compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -83.1% is the lowest of 11, against a peer median of +18.9%.
  • Net income amounts to 6.8% of revenue for TDOC, versus a peer median of 12.5%.
TDOC Competitors
Net Income for TDOC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMNMImmunome, Inc.LTM Sep 2026$282.65M USD+26.9%+79.2%—
EVOEvotec SELTM Mar 2026€196.02M EUR-8.5%-17.3%26.3%
PHVSPharvaris N.V.LTM Sep 2026€179.96M EUR+11.0%+31.9%—
NVCRNovoCure LimitedLTM Mar 2026$173.05M USD+5.4%+13.8%25.7%
TDOCTeladoc Health, Inc.LTM Mar 2026$171.15M USD-83.1%-75.5%6.8%
AZTAAzenta, Inc.LTM Sep 2026$166.99M USD+199.5%+125.1%26.9%
PGNYProgyny, Inc.LTM Jun 2026$102.87M USD+93.6%+24.5%7.8%
SDGRSchrödinger, Inc.LTM Sep 2026$44.01M USD+125.0%-11.5%16.3%
OMDAOmada HealthLTM Mar 2026$24.24M USD-35.6%-43.9%8.6%
OMCLOmnicell, Inc.LTM Mar 2026$20.43M USD-3.5%-28.6%1.7%
PHRPhreesia, Inc.LTM Apr 2026$10.19M USD+123.9%—2.1%
Peer median (excluding TDOC) —+18.9%+13.8%12.5%

Competitors are the stored peer set for TDOC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(428.79M)(13.66B)(220.37M)(1B)(200.32M)
Depreciation & Amortization219.62M267.78M348.72M382.84M363.12M
Deferred Income Tax41.8M(7.84M)(1.9M)(1.15M)(41.41M)
Stock-Based Compensation302.59M217.85M201.55M145.95M80.41M
Change in Working Capital(43.99M)(48.39M)11.64M(36.32M)1.08M
Accounts Receivables(11.17M)(49.06M)(10.25M)(375K)25.13M
Inventory(19.49M)14.8M24.1M(9.75M)399K
Accounts Payables1.19M1.88M(4.19M)(10.37M)11.45M
Other Working Capital(14.51M)(16.01M)1.99M(15.83M)(35.9M)
Other Non-Cash Items102.76M13.42B10.38M803.59M91.48M
Operating Cash Flow193.99M189.29M350.02M293.68M294.36M
Capital Expenditures(8.53M)(16.48M)(156.35M)(10.79M)(8.89M)
Acquisitions (Net)(78.66M)000(81.9M)
Purchases of Investments00000
Sales of Investments60.9M2.51M00740K
Other Investing Activities8.72M2.51M1K(113.26M)(175.95M)
Investing Cash Flow(72.98M)(167.74M)(156.35M)(124.05M)(266M)
Debt Repayment(914K)(3.15M)00(550.63M)
Common Stock Issued42.59M12.39M11.13M8.31M3.09M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(730K)(2.74M)(278K)(2K)(4.11M)
Financing Cash Flow40.95M6.5M10.85M8.31M(551.65M)
Effect of Forex Changes(1.8M)(3.34M)965K(3.29M)6.06M
Net Change in Cash160.16M24.7M205.49M174.65M(517.24M)
Free Cash Flow185.46M172.81M193.67M282.89M285.46M

Teladoc Health, Inc.

NYSE:TDOC

Intrinsic Alpha fair value

Locked

Current Price

$8.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.